File: '\\swfile\EmailIn\20251216 114404 Attachment Asep NR revocation of FFCTO_12162025.docx'

Asep Medical Holdings Inc.

Asep Medical Holdings Announces Revocation of

Failure-to-File Cease Trade Order

December 16, 2025 - Vancouver, British Columbia - Asep Medical Holdings Inc. ("Asep Medical" or the "Company") (CSE: ASEP; OTCQB: SEPSF; FSE: JJ8) announces that its principal regulator, the BC Securities Commission (BCSC), has issued a revocation order lifting the Failure-to-File Cease Trade Order ("FFCTO") previously imposed on the Company.

The FFCTO was originally issued on May 6, 2025, as a result of the Company's delay in filing its annual audited financial statements for the fiscal year ended December 31, 2024, along with the accompanying management's discussion and analysis and related certifications within the prescribed time period under applicable securities regulations.

During the period in which the FFCTO was in effect, the Company continued to operate its core business activities; however, trading in the Company's securities was temporarily restricted. The revocation restores normal trading activity.

Asep Medical remains committed to maintaining strong corporate governance practices and timely financial reporting. With the FFCTO now revoked pursuant to National Policy 11-207 - Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, the Company will continue to advance its strategic initiatives, including the further development and commercialization of its Sepsis Diagnostic (SepsetER(TM)) and Anti-Biofilm Peptide Technology Platforms.

The Company appreciates the patience and continued support of its shareholders and stakeholders throughout this process.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists and the CEO of Asep. Asep holds a controlling interest in two private subsidiary companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin

Asep Medical Holdings Inc.

E. chris@asepmedical.com

T. 604-362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the successful execution of the Company's business plan, the development, testing, and commercialization of its sepsis diagnostic test (Sepset), and other statements regarding the Company's proposed business plans and technologies. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as

required by applicable law.